Physician profile
Anna Durbin
NPI 1326089541
$45,265.98
in general payments reported to CMS, 2019-2025
7 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,111 · 2020: $17K · 2021: $4,175 · 2022: $3,679 · 2023: $220 · 2024: $6,046 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $1,991 · Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,280.00 |
| Travel and Lodging | $1,990.83 |
| Food and Beverage | $504.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15,282.08 | 2019-2024 | |
| Emergent Biosolutions INC. | $10,508.90 | 2025 | |
| Valneva USA, INC. | $8,575.00 | 2020-2022 | |
| Valneva Austria Gmbh | $6,300.00 | 2019-2020 | |
| Roche Diagnostics International LTD | $3,600.00 | 2020 | |
| Modernatx, INC. | $1,000.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Durbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.